Merck KGaA shakes up C-suite Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 21 February, 2025

Join us for an in-depth look at the science shaping biotech’s next breakthroughs. Which pathways, targets and technologies have the potential to steer the next big move in the industry? Register today.

presented by Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

spotlight In Focus Will CRISPR matter?

news Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field Peer Review Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board In Focus Trump blog: Federal judge denies unions' request to halt agency layoffs

Feb 27 10:30am ET Beyond one indication: Unlocking the full potential of orphan drugs sponsored by Catalent Mar 12 11:00am ET Building better biologics: Overcoming hurdles in protein therapy manufacturing sponsored by Catalent Mar 18 10:30am ET Fueling Teva Pharmaceuticals’ spectrum of innovation: Behind the Pivot to Growth strategy sponsored by Teva Pharmaceuticals

Biopharma is always on the hunt for new drug targets and pathways to bolster pipelines — but new modalities and the evolution of AI are redefining what’s next. Join us to find out what will define the next decade of drug discovery.

endpoints pharma Drug packaging manufacturers brace for impact as EU chemical ban looms Roche no longer wants to be where ‘DNA sequencing goes to die’ Trump’s HHS defends drug price negotiations in Novartis suit First meeting of CDC vaccine advisors in the Kennedy era is postponed Drugmakers tell court to keep hospitals out of their 340B rebate suits

in case you missed it 1. How Keymed steered the China-to-US NewCo model in biotech 2. BridgeBio’s heart disease drug Attruby sails past prescription estimates 3. Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so 4. In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms 5.